期刊
TROPICAL MEDICINE & INTERNATIONAL HEALTH
卷 25, 期 5, 页码 540-557出版社
WILEY
DOI: 10.1111/tmi.13382
关键词
canine leishmaniosis; post-marketing pharmacological surveillance; vaccine effectiveness
资金
- European Union's Horizon 2020 research and innovation programme [642609]
- Ministerio de Ciencia y Innovacion, Spain [CG12010-22368-CO2-01]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) [2014SGR26, 2017SGR00924]
- Tropical Disease Cooperative Research Network (RICET) [RD12/0018/0010]
- Montserrat Portus
Canine leishmaniosis is an important vector-borne zoonosis caused mainly by Leishmania infantum. Diagnosis and treatment of affected individuals can be particularly complex, hindering infection control in endemic areas. Methods to prevent canine leishmaniosis include the use of topical insecticides, prophylactic immunotherapy and vaccination. Four vaccines against canine leishmaniosis have been licensed since 2004, two in Brazil (Leishmune (R), the production and marketing licence of which was withdrawn in 2014, and Leish-Tec (R)) and two in Europe (CaniLeish (R) and LetiFend (R)). After several years of marketing, doubts remain regarding vaccine efficacy and effectiveness, potential infectiousness of vaccinated and infected animals or the interference of vaccine-induced antibodies in L. infantum serological diagnosis. This review summarises the scientific evidence for each of the vaccines commercially approved for canine leishmaniosis, while discussing possible weaknesses of these studies. Furthermore, it raises the need to address important questions related to vaccination impact in Leishmania-endemic countries and the importance of post-marketing pharmacological surveillance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据